Trial · NCT02300545
Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
NCT02300545, Phase 2, Completed, Washington University School of Medicine; results first posted 2020-06-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy. Trials, record NCT02300545. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02300545
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
- NCT number
- NCT02300545
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 56 participants, actual
- Lead sponsor
- Washington University School of Medicine
- Conditions
- Sarcoma, Soft Tissue, Soft Tissue Sarcoma
- Interventions
- Pazopanib
- First posted
- 2014-11-25
- Last updated
- 2020-08-05
- Results first posted
- 2020-06-09
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical Benefit Rate | 16 weeks | Clinical benefit rate = complete response (CR) + partial response (PR) + stable disease (SD) * CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. * PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. * SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. |
| Secondary | Progression-free Survival (PFS) | Until disease progression (median follow-up of 10.83 months with full range 0.787-42.26 months) | PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). |
| Secondary | Overall Survival (OS) | Until death (median follow-up of 10.83 months with full range 0.787-42.26 months) | |
| Secondary | Median Overall Change in Quality of Life | Change from baseline to end of treatment (median length of treatment 70 days (5-515 days))) | * Quality of life will be measured using the Functional Assessment of Cancer Therapy-General (FACT-G7) validated survey * 7 statements where the participant can indicate 0 (not at all) up to 4 (very much). The statements include 1) I have lack of energy; 2) I have pain; 3) I have nausea; 4) I worry that my condition will get worse; 5) I am sleeping well; 6) I am able to enjoy life; 7) I am content with the quality of my life right now. * The first 4 statements will negatively affect the total score and the last 3 statements will positively affect the total score * Each item is scored and then added together, multiplied by 7, and divided by the number of items * Total score calculation ranges from 0-28. The higher the score, the better the quality of life |
| Secondary | Clinical Outcome Associated With Serum sVEGFR2 Levels (Serum Levels of sVEGFR2 at Each Time Point Will Plotted and Pearson or Spearman's Correlation Coefficient) | From baseline through completion of treatment | The serum levels of sVEGFR2 at each time point will plotted and Pearson or Spearman's correlation coefficient will be calculated to explore their relationship. |
| Secondary | Clinical Outcome Associated With Serum PICG Levels (Serum Levels of PIGF at Each Time Point Will Plotted and Pearson or Spearman's Correlation Coefficient) | From baseline through completion of treatment | The serum levels of PIGF at each time point will plotted and Pearson or Spearman's correlation coefficient will be calculated to explore their relationship. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Clinical Benefit Rate | 16 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Progression-free Survival (PFS) | Until disease progression (median follow-up of 10.83 months with full range 0.787-42.26 months) | months | MEDIAN | |
| SECONDARY | Overall Survival (OS) | Until death (median follow-up of 10.83 months with full range 0.787-42.26 months) | months | MEDIAN | |
| SECONDARY | Median Overall Change in Quality of Life | Change from baseline to end of treatment (median length of treatment 70 days (5-515 days))) | points on a scale | MEDIAN | |
| SECONDARY | Clinical Outcome Associated With Serum sVEGFR2 Levels (Serum Levels of sVEGFR2 at Each Time Point Will Plotted and Pearson or Spearman's Correlation Coefficient) | From baseline through completion of treatment | There was no funding to process the serum levels of sVEGFR2. | ||
| SECONDARY | Clinical Outcome Associated With Serum PICG Levels (Serum Levels of PIGF at Each Time Point Will Plotted and Pearson or Spearman's Correlation Coefficient) | From baseline through completion of treatment | There was no funding to process the serum levels of PIGF. |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Clinical Benefit Rate | Pazopanib | 22 | Participants | ||
| Progression-free Survival (PFS) | Pazopanib | 3.67 | 95% Confidence Interval 2.62 to 7.25 | months | |
| Overall Survival (OS) | Pazopanib | 14.16 | 95% Confidence Interval 8.46 to NA | months | |
| Median Overall Change in Quality of Life | Pazopanib | 2 | 95% Confidence Interval 0.7356979 to 4.5834510 | points on a scale |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pazopanib | 56 | |
| Overall Study | COMPLETED | Pazopanib | 56 | |
| Overall Study | NOT COMPLETED | Pazopanib | 0 |
Source ClinicalTrials.gov
Adverse events138
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Pazopanib | 18 | 56 | |
| other | Chest pain - cardiac | Cardiac disorders | Pazopanib | 1 | 56 | |
| other | Heart failure | Cardiac disorders | Pazopanib | 1 | 56 | |
| other | Left ventricular systolic dysfunction | Cardiac disorders | Pazopanib | 1 | 56 | |
| other | Palpitations | Cardiac disorders | Pazopanib | 1 | 56 | |
| other | Vertigo | Ear and labyrinth disorders | Pazopanib | 1 | 56 | |
| other | Hyperthyroidism | Endocrine disorders | Pazopanib | 1 | 56 | |
| other | Hypothyroidism | Endocrine disorders | Pazopanib | 4 | 56 | |
| other | Blurred vision | Eye disorders | Pazopanib | 3 | 56 | |
| other | Vision changes | Eye disorders | Pazopanib | 1 | 56 |
1 to 10 of 138Source ClinicalTrials.gov
See all 138 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pazopanib | 24 | 56 |
| Total, other adverse events | Pazopanib | 56 | 56 |
| Total, serious adverse events | Pazopanib | 27 | 56 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02300545
GET https://conductscience.org/api/trials/v1/NCT02300545/events?page=2